Clinical Trial: The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

Study Status: Approved for marketing
Recruit Status: Approved for marketing
Study Type: Expanded Access

Official Title:

Brief Summary: The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Detailed Summary:
Sponsor: Alexion Pharmaceuticals

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Alexion Pharmaceuticals

Dates:
Date Received: February 20, 2007
Date Started:
Date Completion:
Last Updated: May 5, 2014
Last Verified: September 2011